Infectious causes of cancer

AHF Launches New Campaigns “Hook Up With Us” Addressing 6th Straight Year of Increases in STDs and “AHF Is Resilience”

Retrieved on: 
Saturday, June 19, 2021
MEN, General Health, LGBTQ+, Philanthropy, Consumer, Infectious diseases, Foundation, Other Consumer, Marketing, Women, Communications, AIDS, Health, Infectious causes of cancer, Gonorrhea, Disease transmission, Mycoplasma, Sexually transmitted infection, Sexually transmitted diseases and infections, Chlamydia, Clinical medicine, Health, Epidemiology

View the full release here: https://www.businesswire.com/news/home/20210619005059/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210619005059/en/
    In 2019, more than 2.5 million cases of chlamydia, gonorrhea, and syphilis were reported, and were the most common STDs found.
  • Undoubtedly, this causes grave concern as STDs have the potential to lead to serious health consequences, especially if untreated.
  • Past AHF billboard campaigns addressing STDs include Gonorrhea Alert , launched in June of 2018 which was a nationwide effort to educate the public about a drug-resistant strain of the STD.
  • To learn more about AHF, please visit our website: www.aidshealth.org , find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare .

Global HPV Testing and Pap Test Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 17, 2021
Oncology, Health, Consumer, Infectious diseases, Women, Other Health, Cancer, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Cervical screening, Pap test, Cervical cancer, Human papillomavirus infection, Cancer screening, Vagina, Screening, HPV vaccine

The "HPV Testing and Pap Test Market Size, Share & Trends Analysis Report by Test Type, by Application (Cervical Cancer Screening, Vaginal Cancer Screening), by Product, by Technology, by End Use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "HPV Testing and Pap Test Market Size, Share & Trends Analysis Report by Test Type, by Application (Cervical Cancer Screening, Vaginal Cancer Screening), by Product, by Technology, by End Use, by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global HPV testing and Pap test market size is expected to reach USD 7.3 billion by 2028.
  • In addition, approval of novel testing solutions and services to upsurge screening rates is further anticipated to support market growth.
  • Based on test type, the Pap test segment accounted for the largest revenue share in 2020, owing to its widespread use in cervical cancer screening programs.

Turning Point Therapeutics Granted FDA Orphan Drug Designation for TPX-0022 in Gastric Cancer

Retrieved on: 
Thursday, June 17, 2021
Health sciences, Health, Drugs, Breakthrough therapy, Orphan drugs, Protein kinase inhibitors, Infectious causes of cancer, c-Met inhibitor, Cancer research, Stomach cancer, ALK inhibitor, ROS1

We are pleased to receive this designation for TPX-0022 as we work to develop it as a potentially differentiated option for patients affected by MET-driven gastric cancer.

Key Points: 
  • We are pleased to receive this designation for TPX-0022 as we work to develop it as a potentially differentiated option for patients affected by MET-driven gastric cancer.
  • There are currently no approved MET inhibitors for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma.
  • Orphan Drug Designation is granted by the FDA to assist in the development of drug candidates that may offer therapeutic benefits for diseases with a prevalence of fewer than 200,000 patients annually.
  • The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

VBI Vaccines to Present at Upcoming Scientific Conferences

Retrieved on: 
Thursday, June 17, 2021
Research, Infectious diseases, FDA, Clinical trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Medical specialties, Clinical medicine, Health, Vaccines, Infectious causes of cancer, Viral diseases, Virology, Animal virology, Hepatitis, Vaccine, Virus, Coronavirus, Hepatitis B, VBI’s 3-Antigen Hepatitis B Vaccine, VBI Vaccines Inc., HEPATITIS B, VBI’S 3-ANTIGEN HEPATITIS B VACCINE, VBI VACCINES INC.

Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.

Key Points: 
  • Hepatitis B is one of the worlds most significant infectious disease threats with more than 290 million people infected globally.
  • To learn more about VBIs 3-Antigen Hepatitis B vaccine candidate visit: https://www.vbivaccines.com/sci-b-vac/
    VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM).
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Praedicare Inc. Receives Grant to Evaluate Potential New Drug Regimens for Tuberculosis

Retrieved on: 
Thursday, June 17, 2021
Biotechnology, General Health, Hospitals, Health, Pharmaceutical, Medical specialties, Tuberculosis, Infectious diseases, Microbiology, Infectious causes of cancer, Acid-fast bacilli, Pathogenic bacteria, Health in Africa, Mycobacterium tuberculosis, Mycobacterium, Drug development

Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicares in vitro hollow fiber model of Tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.

Key Points: 
  • Praedicare Inc., a CRO using unique pre-clinical laboratory and proprietary mathematical translation models today announced it has been awarded a two-year, $2.8 million grant by the Bill & Melinda Gates Foundation to evaluate novel TB drug regimens using Praedicares in vitro hollow fiber model of Tuberculosis (TB) in identifying potential new drug regimens that shorten treatment times for the disease.
  • The study will also include pharmacokinetic and pharmacodynamic evaluation of the drugs.
  • TB is caused by Mycobacterium tuberculosis that most often affects the lungs.
  • Praedicare Inc. is an end-to-end drug development company, from drug discovery, through preclinical work, to phase IV clinical trials.

Villya Pharmaceuticals Announces Patent Approval for 2 New Drugs to Treat FGS

Retrieved on: 
Tuesday, June 15, 2021
Medical specialties, Infectious diseases, Clinical medicine, Tropical diseases, Helminthiases, Waterborne diseases, Infectious causes of cancer, Neglected tropical diseases, Schistosomiasis, Schistosoma haematobium, Infection, HIV

Up to 50% of the women having Schistosomiasis haematobium suffer from female genital schistosomiasisor FGS.

Key Points: 
  • Up to 50% of the women having Schistosomiasis haematobium suffer from female genital schistosomiasisor FGS.
  • Though the greatest risk is the open lesions caused by FGS that leave the subject susceptible to HIV and other infections.
  • William Miller, CEO at Villya Pharmaceuticals says "FGS is a neglected tropical disease for which there was no specific treatment until now.
  • Miller continued by saying "Villya designed these two new drugs specifically to eliminate this disease.

Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, June 14, 2021
Medicine, Health, Vaccines, Medical research, Vaccitech, Infectious causes of cancer, Papillomavirus, Human papillomavirus infection

OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments.

Key Points: 
  • OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced financial results for the quarter ended March 31, 2021, and provided an overview of the Companys recent corporate developments.
  • The first quarter of 2021 was transformational for Vaccitech as we closed a Series B financing round and initiated patient dosing in our two lead therapeutic programs, HBV and HPV, said Bill Enright, CEO of Vaccitech.
  • Subsequent to the end of the first quarter, the Company closed an initial public offering that raised a gross amount of $110.5 million.
  • Research and development (R&D) expenses: Research and development expenses were $4.6 million for the first quarter of 2021 compared to $4.2 million for the comparable period of the prior year.

New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer

Retrieved on: 
Monday, June 14, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical trials, Anatomy, Infectious causes of cancer, Branches of biology, Clinical medicine, Histopathology, Prostate cancer, Biopsy, Prostate, Cancer, Bladder cancer, MCRPC, Thyroid cancer, Decipher Prostate, Veracyte, DECIPHER PROSTATE, VERACYTE

(Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the companys Decipher Prostate genomic classifier among men with non-metastatic castration-resistant prostate cancer (nmCRPC) have been published online in JAMA Oncology .

Key Points: 
  • (Nasdaq: VCYT) today announced new data demonstrating the prognostic utility of the companys Decipher Prostate genomic classifier among men with non-metastatic castration-resistant prostate cancer (nmCRPC) have been published online in JAMA Oncology .
  • The test stratified patient tumors into Decipher high- and low-to-average-risk groups for metastasis and into basal and luminal subtypes.
  • Decipher Prostate (Decipher Prostate Biopsy and Decipher Prostate RP) is a 22-gene, whole-transcriptome-developed genomic test intended to help inform treatment decisions for men with localized prostate cancer at initial diagnosis and after surgical removal of the prostate.
  • The companys tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping and renal cancer tests are in development.

Clinical Genomics Announces Three Poster Presentations at ASCO 2021 Annual Meeting, Including New Data Highlighting Clinical Utility of COLVERA® Liquid Biopsy for Colorectal Cancer Recurrence Detection and Prediction of Clinical Outcomes

Retrieved on: 
Monday, June 14, 2021
Clinical medicine, Medicine, Branches of biology, Oncology, Anatomical pathology, DNA, Medical signs, Infectious causes of cancer, Circulating tumor DNA, Colorectal cancer, Assay

COLVERA is a first of its kind blood test to detect circulating tumor DNA for MRD assessment and recurrence monitoring.

Key Points: 
  • COLVERA is a first of its kind blood test to detect circulating tumor DNA for MRD assessment and recurrence monitoring.
  • With these improvements, COLVERA differentiates more accurately between patients with and without recurrent disease, and thus is clinically more informative.
  • https://meetings.asco.org/abstracts-presentations/196522
    Included two cohorts of CRC patients (N=322 and N=144) evaluating the impact of optimizing the assays actionability for CRC recurrence detection.
  • Clinical Genomics is dedicated to improving patient outcomes through early detection of colorectal cancer.

G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

Retrieved on: 
Monday, June 14, 2021
Cancer, Clinical medicine, Chemical compounds, Breakthrough therapy, G1 Therapeutics, Infectious causes of cancer, Orphan drugs, Trilaciclib, Bladder cancer, Avelumab, Chemotherapy, Gemcitabine

Arm B will receive COSELA prior to gemcitabine/platinum chemotherapy followed by COSELA plus avelumab maintenance therapy.

Key Points: 
  • Arm B will receive COSELA prior to gemcitabine/platinum chemotherapy followed by COSELA plus avelumab maintenance therapy.
  • Bladder cancer is the most common malignancy involving the urinary system and is the sixth most common cancer in the United States.
  • The American Cancer Society estimates that approximately 84,000 new cases of bladder cancer will be diagnosed in the U.S. in 2021.
  • G1 Therapeutics and the G1 Therapeutics logo and COSELA and the COSELA logo are trademarks of G1 Therapeutics, Inc.